Comparison of GnRH antagonist and GnRH agonist used in IVF-ET in patients with PCOS

Abstract

Abstract: AIM: To compare the effect of the GnRH antagonist and GnRH agonist on the outcomes of polycystic ovary syndrome patients who underwent in vitro fertilization and embryo transfer. METHODS: The study started from July 2012 to December 2012. A total of 122 patients with PCOS were divided into two groups according to the will of patients: 54 cycles in group A underwent GnRH antagonist protocol and 68 cycles in group B underwent routine GnRH agonist protocol. The dosage of gonadotropin, hormone levels, laboratory results, OHSS incidence and clinical outcomes were compared between the two groups. RESULTS:Total dosage and duration of gonadotropin of group A were (1 342.82±442.56) IU and (9.67±2.06) d, which was significantly lower than that of group B (1 521.32±506.59) IU and (12.01±3.62) days. E₂ on the day of HCG administration of Group A (12 354.43±5 771.43) pmol/L was significantly higher than that of group B (8 685.26±4 218.03) pmol/L. The fertilization rate and blastocyst formation rate of group A (79.3% and 73.76%) were significantly higher compared with group B (39.33% and 30.71%). The clinical pregnancy rates were 44.90% and 66.67% respectively. Group B had a rising trend but there had no significant difference. The other laboratory results, OHSS incidence and clinical outcomes were not significant difference. CONCLUSION: Compared with GnRH agonist protocol, GnRH antagonist protocol effectively reduced the amount and duration of gonadotriopin, cut down the costs and relieved the psychological burden. In addition, GnRH antagonist protocol improved the blastocyst formation rate, which may indirectly increased the cumulative pregnancy rate. We concluded that GnRH antagonist protocol may be an alternative method for PCOS patients.

Key words: GnRH antagonist, GnRH agonist, PCOS, IVF-ET, OHSS

CLC Number:

R588

WANG Pei-yu, YU Rong, LIN Jin-ju, XIAO Shi-quan, JIN Cong-cong, ZHU Ru-ru. Comparison of GnRH antagonist and GnRH agonist used in IVF-ET in patients with PCOS[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 795-800.

References

[1] Lainas TG, Sfontouris IA, Zorzovilis IZ, et al.Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomized controlled trial (RCT)[J]. Hum Reprod, 2010, 25(3): 683-689.
[2] Rotterdam ESHRE /ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(1): 19-25.
[3] Abraham G, Ariel W.Symposium: Update on prediction and management of OHSS, A modern classification of OHSS[J]. Reprod Biomed Online, 2009, 19(1): 28-32.
[4] MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome[J]. Hum Reprod, 1992, 7(5): 597-600.
[5] Felberbaum RE, Dieduick K.Gonadotrophin-releasing hormone antagonists: will they replace the agonists[J]? Reprod biomed Online, 2003, 6(1): 43-53.
[6] Bahceci M, Ulug U, Ben-Shlomo I, et al.Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study[J]. J Reprod Med, 2005, 50(2): 84-90.
[7] Lainas TG, Petsas GK, Zorzovilis IZ, et al.Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development[J]. Hum Reprod, 2007, 22(6): 1540-1546.
[8] Ragni G, Vegetti W, Riccaboni A, et al.Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome[J]. Hum Reprod, 2005, 20(9): 2421-2425.
[9] Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles[J]. Cochrane Database Syst Rev, 2011, 19(1): CD008046.
[10] Radesic B, Tremellen K.Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates[J]. Hum Reprod, 2011, 26(12): 3437-3442.
[11] Humaidan P, Polyzos NP, Alsbjerg B, et al.GnRHa trigger and individualized luteal phasehCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients[J]. Hum Reprod, 2013, 28(9): 2511-2521.
[12] Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology[J]. Cochrane Database Syst Rev, 2011, 11(5): CD001750.
[13] Xiao J, Chen S, Zhang C, et al.Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis[J]. Gynecol Endocrinol, 2013, 29(3): 187-191.